Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
This facilitated interpretation of myostatin and propeptide concentrations within the context of a given amount of lean mass.Descriptive characteristics of younger, older, and sarcopenic older women and men (n = 240)YoungerOlderSarcopenic(n = 40)(n = 40)(n = 40)Women Clinical variables Age (years)32.3 ± 5.576.0 ± 8.6*78.4 ± 8.2** Weight (kg)69.2 ± 17.478.2 ± 13.9*68.1 ± 11.9*** Height (cm)165 ± 6.3160 ± 6.0*160 ± 6.5** BMI (kg/m2)25.3 ± 5.930.6 ± 4.6*26.7 ± 3.9*** Relative ASM (kg/m2)5.9 ± 0.66.1 ± 0.74.9 ± 0.4**,*** TBLM (kg)37.4 ± 3.937.9 ± 5.331.1 ± 3.3 **,*** TBLM/weight0.56 ± 0.110.49 ± 0.07*0.47 ± 0.07** TBFM (kg)28.2 ± 14.537.4 ± 10.4*33.4 ± 9.7 TBFM/weight0.38 ± 0.110.47 ± 0.07*0.48 ± 0.07** Muscle strength Grip strength (kg)27.5 ± 5.122.7 ± 5.1*19.9 ± 3.4***** Knee extensor strength (kg)69.6 ± 16.952.7 ± 16.5*42.9 ± 9.8***** Physical activity Energy expenditure (kcal/week)30837 ± 774425399 ± 6125*22645 ± 6451**Men Clinical variables Age (years)33.0 ± 3.874.8 ± 7.3*78.9 ± 6.8**,*** Weight (kg)92.3 ± 16.789.7 ± 15.675.9 ± 9.6**,*** Height (cm)179 ± 5.8175 ± 6.0*171 ± 7.2**,*** BMI (kg/m2)28.8 ± 4.729.2 ± 4.026.0 ± 2.4**,*** Relative ASM (kg/m2)8.5 ± 1.07.9 ± 0.4*6.7 ± 0.5**,*** TBLM (kg)57.6 ± 7.354.7 ± 4.245.9 ± 4.9**,*** TBLM/weight0.63 ± 0.080.62 ± 0.080.61 ± 0.07 TBFM (kg)30.7 ± 12.031.6 ± 12.526.5 ± 7.3*** TBFM/weight0.32 ± 0.080.34 ± 0.080.34 ± 0.06 Muscle strength Grip strength (kg)50.4 ± 9.539.2 ± 7.4*33.7 ± 7.4**,*** Knee extensor strength (kg)122 ± 33.780.7 ± 19.1*61.7 ± 16.8**,*** Physical activity Energy expenditure (kcal/week)40136 ± 1435034222 ± 9090*27009 ± 7008**,***Values are presented as mean ± SD and p values BMI body mass index, ASM appendicular skeletal muscle mass, TBLM total body lean mass, TBFM total body fat mass*p < 0.05 younger vs. older; **p < 0.05 younger vs. sarcopenic; ***p < 0.05 older vs. sarcopenicBiochemical parameters in younger, older and sarcopenic older women and men (n = 240)YoungerOlderSarcopenic(n = 40)(n = 40)(n = 40)Women Biochemical variables Myostatin (ng/mL)5.5 (3.2 to 7.3)7.3 (5.7 to 11.7)*5.3 (4.2 to 8.0)*** Myostatin/TBLM (ng/ml/kg)0.142 (0.091 to 0.195)0.199 (0.138 to 0.327)*0.175 (0.145 to 0.255)** Propeptide (ng/ml)7.1 (5.2 to 10.8)11.4 (7.3 to 20.1)*10.0 (6.5 to 12.4)*** Propeptide/TBLM (ng/ml/kg)0.194 (0.139 to 0.294)0.292 (0.186 to 0.203)*0.307 (0.203 to 0.417)** FLRG (ng/mL)5.1 (4.3 to 6.0)7.3 (6.2 to 9.7)*8.3 (6.7 to 10.6)** GASP1 (ng/mL)7.6 (6.5 to 10.1)9.4 (7.2 to 11.0)9.2 (7.1 to 12.2)** Total 25-(OH)D (ng/mL)25.0 (17.3 to 34.8)20.0 (14.3 to 24.0)*18.5 (14.0 to 24.8)** IGF-1 (ng/mL)235 (191 to 305)141 (93 to 183)*105 (78 to 147)**,*** IGF-2 (ng/mL)1160 (958 to 1375)1112 (933 to 1367)1167 (884 to 1336) IGFBP-2 (ng/mL)406 (190 to 621)447 (308 to 775)635 (539 to 987)**,*** IGFBP-3 (ng/mL)4580 (4099 to 5094)4096 (3536 to 4513)*3913 (3171 to 4389)** Total E1 (pg/mL)47.0 (33.3 to 57.8)31.0 (19.0 to 37.0)*23.0 (16.0 to 29.0)** Total E2 (pg/mL)54.0 (30.5 to 108.5)5.6 (4.2 to 9.1)*4.9 (3.2 to 7.3)** Total T (ng/dL)23.5 (18.0 to 30.0)16.0 (12.0 to 24.0)*21.0 (11.0 to 30.0) Bio E2 (pg/mL)15.0 (8.2 to 28.2)2.1 (1.0 to 3.2)*1.0 (0.6 to 1.7)**,*** Bio T (ng/dL)1.5 (0.9 to 2.1)1.5 (1.0 to 2.6)1.1 (0.7 to 1.8)*** SHBG (nmol/L)63.1 (45.0 to 95.6)40.5 (23.2 to 57.8)*52.8 (46.7 to 73.0)***Men Biochemical variables Myostatin (ng/mL)10.5 (9.0 to 14.4)7.1 (5.4 to 8.8)*6.9 (4.4 to 8.9)** Myostatin/TBLM (ng/ml/kg)0.192 (0.156 to 0.241)0.131 (0.101 to 0.164)*0.153 (0.092 to 0.192)** Propeptide (ng/ml)15.7 (11.7 to 19.4)11.8 (7.6 to 15.7)10.8 (6.4 to 14.9)** Propeptide/TBLM (ng/ml/kg)0.276 (0.207 to 0.328)0.216 (0.137 to 0.305)0.240 (0.153 to 0.309) FLRG (ng/mL)4.5 (3.8 to 5.3)7.5 (6.1 to 9.4)*7.4 (6.3 to 9.9)** GASP1 (ng/mL)9.4 (7.5 to 10.6)9.4 (7.3 to 10.7)10.3 (8.9 to 11.9) Total 25-(OH)D (ng/mL)23.5 (17.0 to 31.8)21.5 (17.0 to 25.8)21.0 (16.0 to 26.8) IGF-1 (ng/mL)344 (292 to 446)193 (114 to 245)*169 (103 to 245)** IGF-2 (ng/mL)1099 (1005 to 1226)961 (774 to 1075)*964 (785 to 1071)** IGFBP-2 (ng/mL)244 (142 to 361)547 (391 to 728)*758 (531 to 1049)** IGFBP-3 (ng/mL)4469 (3833 to 4988)3202 (2596 to 3581)*3230 (2613 to 4019)**,*** Total E1 (pg/mL)32.5 (25.3 to 38.0)35.0 (30.0 to 45.0)*31.0 (25.5 to 44.0) Total E2 (pg/mL)23.0 (19.0 to 30.0)25.0 (20.0 to 28.0)23.0 (18.0 to 29.0) Total T (ng/dL)462 (392 to 549)424 (321 to 526)484 (388 to 609) Bio E2 (pg/mL)12.8 (11.0 to 17.5)9.5 (7.1 to 11.0)*7.4 (5.5 to 10.0)** Bio T (ng/dL)133 (115 to 156)50.8 (37.0 to 63.5)*50.8 (37.4 to 62.7)** SHBG (nmol/L)25.1 (19.4 to 31.3)45.5 (39.0 to 58.6)*50.3 (39.9 to 64.0)**Values are presented as median (IQR) TBLM total body lean mass, FLRG follistatin-related gene protein, GASP-1 growth and serum protein-1, 25(OH)D 25-hydroxyvitamin D, IGF insulin-like growth factor, IGFBP IGF-binding protein, E 1 estrone, E 2 estradiol, T testosterone; SHBG sex hormone-binding globulin*p < 0.05 younger vs. older; **p < 0.05 younger vs. sarcopenic; ***p < 0.05 older vs. sarcopenic
Source: Clinical characteristics of the study subjects. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The older women and older men were then each divided into two groups of 40 subjects based on their relative appendicular skeletal muscle mass (rASM).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay
Study design awaiting verification · Skeletal Muscle · 2015
Original publication title
Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay
© Bergen III et al. 2015
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Myostatin is a protein synthesized and secreted by skeletal muscle that negatively regulates muscle mass. The extent to which circulating myostatin levels change in the context of aging is controversial, largely due to methodological barriers.
Source: BackgroundAbstract: What methods does the paper describe?
We developed a specific and sensitive liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay to measure concentrations of myostatin and two of its key inhibitors, follistatin-related gene (FLRG) protein and growth and serum protein-1 (GASP-1) in 80 younger (<40 years), 80 older (>65 years), and 80 sarcopenic older women and men.
Source: MethodsAbstract: Electronic supplementary material
The online version of this article (doi:10.1186/s13395-015-0047-5) contains supplementary material, which is available to authorized users.
Source: Electronic supplementary materialAbstract: Results
Older women had 34 % higher circulating concentrations of myostatin than younger women. Per unit of lean mass, both older and sarcopenic older women had >23 % higher myostatin levels than younger women. By contrast, younger men had higher myostatin concentrations than older men with and without sarcopenia. Younger men had approximately twofold higher concentrations of myostatin than younger women; however, older women and sarcopenic older women had significantly higher relative myostatin levels than the corresponding groups of men. In both sexes, sarcopenic older subjects had the highest concentrations of FLRG.
Circulating concentrations of myostatin exhibited positive, but not robust, correlations with relative muscle mass in both sexes.
Source: ResultsAbstract: Conclusions
Our data suggest that myostatin may contribute to the higher prevalence of sarcopenia in women but acts as a homeostatic regulator of muscle mass in men. Moreover, this new LC-MS/MS-based approach offers a means to determine the extent to which myostatin serves as a biomarker of muscle health in diverse conditions of muscle loss and deterioration.
Source: ConclusionsAuthors’ abstract
Background
Myostatin is a protein synthesized and secreted by skeletal muscle that negatively regulates muscle mass. The extent to which circulating myostatin levels change in the context of aging is controversial, largely due to methodological barriers.
Methods
We developed a specific and sensitive liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay to measure concentrations of myostatin and two of its key inhibitors, follistatin-related gene (FLRG) protein and growth and serum protein-1 (GASP-1) in 80 younger (<40 years), 80 older (>65 years), and 80 sarcopenic older women and men.
Results
Older women had 34 % higher circulating concentrations of myostatin than younger women. Per unit of lean mass, both older and sarcopenic older women had >23 % higher myostatin levels than younger women. By contrast, younger men had higher myostatin concentrations than older men with and without sarcopenia. Younger men had approximately twofold higher concentrations of myostatin than younger women; however, older women and sarcopenic older women had significantly higher relative myostatin levels than the corresponding groups of men. In both sexes, sarcopenic older subjects had the highest concentrations of FLRG.
Circulating concentrations of myostatin exhibited positive, but not robust, correlations with relative muscle mass in both sexes.
Conclusions
Our data suggest that myostatin may contribute to the higher prevalence of sarcopenia in women but acts as a homeostatic regulator of muscle mass in men. Moreover, this new LC-MS/MS-based approach offers a means to determine the extent to which myostatin serves as a biomarker of muscle health in diverse conditions of muscle loss and deterioration.
Electronic supplementary material
The online version of this article (doi:10.1186/s13395-015-0047-5) contains supplementary material, which is available to authorized users.
Publication and source details
Original title: Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay
H. Robert Bergen III; Joshua N. Farr; Patrick M. Vanderboom; Elizabeth J. Atkinson; Thomas A. White; Ravinder J. Singh; Sundeep Khosla; Nathan K. LeBrasseur
Skeletal Muscle · 2015
© Bergen III et al. 2015https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T20:26:35.331713+00:00
DOI: 10.1186/s13395-015-0047-5 · PMC4502935